For June 2026, WUXI BIO (WuXi Biologics Cayman Inc.) reported a net issuance of 2.45 million new ordinary shares, expanding its outstanding share count to 4.14 billion. The increase was driven entirely by option exercises under four Pre-IPO Share Option Schemes, which collectively generated USD 0.57 million in cash proceeds.

The company’s authorised share capital remained unchanged at USD 50,000, equivalent to 6.00 billion ordinary shares with a par value of USD 0.000008333333 each.

Public-float requirements continue to be met, with at least 15% of total issued shares held by the public as of 30 June 2026. No treasury shares were issued, cancelled, or transferred during the month.

Option activity: • 2.45 million options were exercised, reducing outstanding Pre-IPO options to 26.38 million. • No new options were granted, and the Pre-IPO scheme is closed to further grants.

Share award capacity: • Up to 89.55 million ordinary shares remain available for issuance under the company’s Restricted Share Award Scheme. • An additional 9.23 million shares may be issued under the Global Partner Program Share Award Scheme.

Share repurchases: • A cumulative 37.11 million ordinary shares were repurchased between 27 May and 30 June 2026 but had not yet been cancelled as of month-end (4.51 million in May; 16.58 million in early June; 16.01 million in mid-to-late June). These repurchased shares are pending cancellation and therefore do not yet affect the issued-share total.

No new warrants, convertibles, or other equity instruments were issued during the period. The board has confirmed full compliance with Hong Kong Stock Exchange listing rules and regulatory requirements.